The Exchange had sought clarification from Aarti Pharmalabs Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE had asked Aarti Pharmalabs to clarify certain aspects of its financial results for the quarter ended 30 June 2025, under Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements. The company has submitted its response to the exchange, the details of which are enclosed with the filing. The specific points of clarification are not detailed in the headline. Regulation 33 typically relates to the submission and accuracy of quarterly financial results.
This appears to be a routine compliance clarification on financial results and is not necessarily indicative of any serious regulatory or governance issue. Investors should monitor for any follow-up actions from the exchange or further details from the company on the nature of the clarification.